Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bcp.14102 http://scihub22266oqcxt.onion/10.1111/bcp.14102 31454097!6955400!31454097     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Clin+Pharmacol 2019 ; 85 (12): 2747-2758 Nephropedia Template TP {{tp|p=31454097|t=2019. CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis |pdf=|usr=}}{{31454097}} gab.com Text CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis JO: Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=31454097 #FOAvip AIMS: Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration-response relationship of rituximab in RA patients. METHODS: In this retrospective monocentric observational study, 52 patients were assessed. Repeated measurements of rituximab concentrations (pharmacokinetics), CD4+ counts (biomarker) and disease activity score in 28 joints (DAS28, clinical response) were made. Rituximab pharmacokinetics was described using a 2-compartment model, and CD4+ cell counts and DAS28 measurements were described using indirect turnover and direct Emax pharmacokinetic-pharmacodynamic models, respectively. Delay between rituximab concentrations and responses was accounted for by including biophase compartments. RESULTS: Elimination half-life of rituximab was 18 days. The pharmacokinetic-pharmacodynamic model showed that DAS28 response to rituximab was partly associated with CD4+ cell depletion. At 6 months, a deeper DAS28 decrease was observed in patients when CD4+ cell count is decreased: median [interquartile range] of DAS28 was 3.7 [2.9-4.4] and 4.5 [3.7-5.3] in patients with and without CD4+ decrease, respectively. CONCLUSIONS: This is the first study to quantify the relationship between rituximab concentrations, CD4+ count and DAS28 in RA patients. This model showed that approximately 75% of patients had CD4+ count decrease, and that the clinical improvement is 2-fold higher in patients with CD4+ cells decrease than in others. Twit Text FOAVip CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis ????Br J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=31454097 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=31454097 #FOAvip English Wikipedia <ref>{{Cite pmid|31454097}}</ref> CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis #MMPMID31454097 Bensalem A; Mulleman D; Thibault G; Azzopardi N; Goupille P; Paintaud G; Ternant D Br J Clin Pharmacol 2019[Dec]; 85 (12): 2747-2758 PMID31454097show ga AIMS: Rituximab is approved in rheumatoid arthritis (RA). A substantial decrease in CD4+ count was observed in responders after a single cycle of treatment. This study aimed to describe and quantifying the influence of CD4+ count depletion on the concentration-response relationship of rituximab in RA patients. METHODS: In this retrospective monocentric observational study, 52 patients were assessed. Repeated measurements of rituximab concentrations (pharmacokinetics), CD4+ counts (biomarker) and disease activity score in 28 joints (DAS28, clinical response) were made. Rituximab pharmacokinetics was described using a 2-compartment model, and CD4+ cell counts and DAS28 measurements were described using indirect turnover and direct Emax pharmacokinetic-pharmacodynamic models, respectively. Delay between rituximab concentrations and responses was accounted for by including biophase compartments. RESULTS: Elimination half-life of rituximab was 18 days. The pharmacokinetic-pharmacodynamic model showed that DAS28 response to rituximab was partly associated with CD4+ cell depletion. At 6 months, a deeper DAS28 decrease was observed in patients when CD4+ cell count is decreased: median [interquartile range] of DAS28 was 3.7 [2.9-4.4] and 4.5 [3.7-5.3] in patients with and without CD4+ decrease, respectively. CONCLUSIONS: This is the first study to quantify the relationship between rituximab concentrations, CD4+ count and DAS28 in RA patients. This model showed that approximately 75% of patients had CD4+ count decrease, and that the clinical improvement is 2-fold higher in patients with CD4+ cells decrease than in others. |*Models, Biological[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antirheumatic Agents/administration & dosage/adverse effects/*blood/therapeutic use[MESH] |Arthritis, Rheumatoid/blood/*drug therapy[MESH] |Biomarkers/analysis[MESH] |CD4 Lymphocyte Count[MESH] |CD4-Positive T-Lymphocytes/*drug effects[MESH] |Dose-Response Relationship, Drug[MESH] |Female[MESH] |Half-Life[MESH] |Humans[MESH] |Male[MESH] |Markov Chains[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Rituximab/administration & dosage/adverse effects/*blood/therapeutic use[MESH]CD4+ count-dependent concentration-effect relationship of rituximab in(epmc).pdf DeepDyve Pubget Overpricing